- Home
- ABUS vs BCYC Comparison
ABUS vs BCYC Comparison
Compare ABUS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- BCYC
- Stock Information
- Founded
- ABUS 2005
- BCYC 2009
- Country
- ABUS United States
- BCYC United Kingdom
- Employees
- ABUS N/A
- BCYC N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- ABUS Health Care
- BCYC Health Care
- Exchange
- ABUS Nasdaq
- BCYC Nasdaq
- Market Cap
- ABUS 672.1M
- BCYC 566.5M
- IPO Year
- ABUS N/A
- BCYC 2019
- Fundamental
- Price
- ABUS $3.08
- BCYC $8.10
- Analyst Decision
- ABUS Strong Buy
- BCYC Buy
- Analyst Count
- ABUS 4
- BCYC 10
- Target Price
- ABUS $5.50
- BCYC $25.00
- AVG Volume (30 Days)
- ABUS 827.5K
- BCYC 376.0K
- Earning Date
- ABUS 05-14-2025
- BCYC 05-01-2025
- Dividend Yield
- ABUS N/A
- BCYC N/A
- EPS Growth
- ABUS N/A
- BCYC N/A
- EPS
- ABUS N/A
- BCYC N/A
- Revenue
- ABUS $6,403,000.00
- BCYC $25,722,000.00
- Revenue This Year
- ABUS $14.57
- BCYC N/A
- Revenue Next Year
- ABUS $15.84
- BCYC $1.70
- P/E Ratio
- ABUS N/A
- BCYC N/A
- Revenue Growth
- ABUS N/A
- BCYC N/A
- 52 Week Low
- ABUS $2.63
- BCYC $6.10
- 52 Week High
- ABUS $4.72
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- ABUS 39.99
- BCYC 47.67
- Support Level
- ABUS $2.94
- BCYC $7.83
- Resistance Level
- ABUS $3.42
- BCYC $9.00
- Average True Range (ATR)
- ABUS 0.18
- BCYC 0.60
- MACD
- ABUS -0.04
- BCYC 0.00
- Stochastic Oscillator
- ABUS 17.72
- BCYC 32.87
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.